- Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation
-
Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Park JS
- KMID: 2344173
- J Korean Med Sci.
- 2015 Oct;30(10):1416-1422.
- doi: 10.3346/jkms.2015.30.10.1416
For decades, maintenance chemotherapy has failed to improve the cure rate or prolong the survival of patients with acute myeloid leukemia (AML), other than those with acute promyelocytic leukemia. Immediately... -
- CITED
-
- Close
- SHARE
-
- Close
- The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia
-
Lee SR, Yang DH, Ahn JS, Kim YK, Lee JJ, Choi YJ, Shin HJ, Chung JS, Cho YY, Chae YS, Kim JG, Sohn SK, Kim HJ
- KMID: 1779170
- J Korean Med Sci.
- 2009 Jun;24(3):498-503.
- doi: 10.3346/jkms.2009.24.3.498
A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age,... -
- CITED
-
- Close
- SHARE
-
- Close
- Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia
-
Park H, Chung H, Lee J, Jang J, Kim Y, Kim SJ, Kim JS, Min YH, Cheong JW
- KMID: 2374186
- Yonsei Med J.
- 2017 Jan;58(1):35-42.
- doi: 10.3349/ymj.2017.58.1.35
PURPOSE: Decitabine, a DNA hypomethylating agent, was recently approved for use in Korea for older adults with acute myeloid leukemia (AML) who are not candidates for standard chemotherapy. This study... -
- CITED
-
- Close
- SHARE
-
- Close
- Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea
-
Lee DH, Chung NG, Cho B, Kim HK, Kang HJ, Shin HY, Ahn HS, Yoo KH, Sung KW, Koo HH, Kook H, Hwang TJ, Im HJ, Seo JJ, Park HJ
- KMID: 1713825
- J Korean Med Sci.
- 2010 Jan;25(1):9-15.
- doi: 10.3346/jkms.2010.25.1.9
We investigated the outcome of idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosyl cytosine (BHAC)-based chemotherapy (BHAC group, n=149) compared to idarubicin plus cytarabine-based chemotherapy (cytarabine group, n=191) for childhood acute myeloid leukemia (AML). Between... -
- CITED
-
- Close
- SHARE
-
- Close
